Ranolazine in Ischemic Cardiomyopathy

Completed · Phase 4 · Has a placebo group

Conditions studied: Cardiomyopathy, Chest Pain, Dyspnea

In brief

Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.

Key facts

Study ID

NCT01345188

Run by

Midwest Cardiovascular Research Foundation

People needed

28

Starts

2011-04-01

Expected to finish

2014-04-01

Last updated by the study team

2024-12-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ischemic cardiomyopathy patients on optimal medical treatment. Optimal medical treatment is defined as the continued symptoms of chest pain or dyspnea despite treatment with 2 antiischemic agents (beta blockers, CCB or nitrates). Unless contraindicated, all cardiomyopathy patients should be treated with a beta blocker and an ACEI/ARB.
• Anginal chest pain or dyspnea
• Documentation of non treatable or optimally treated coronary artery disease
• Ejection Fraction of less than or equal to 40%

You may not qualify if…

• Less than 18 years of age
• Pregnant or breast feeding
• Patients with non ischemic cardiomyopathy

Where it is running

• Midwest Cardiovascular Research Foundation — Davenport, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.